An Observational Prospective Study to Understand the Usage Pattern of Ticagrelor With ACS (Acute Coronary Syndrome)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

3000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-04-27

Study Completion Date

2017-06-24

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The TREASURE observational study is designed to address the need to understand the usage pattern of Ticagrelor in real life scenario in large number of ACS (Acute Coronary Syndrome) patients in India. The aim of this national study is to understand the usage pattern (including the duration of treatment) of Ticagrelor in various ACS patient population undergoing PCI (Percutaneous Coronary Intervention), CABG (Coronary Artery Bypass Graft) or medical management in a real-life setting in India.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Assessment of Coronary Flow Reserve by Doppler Flow WIre in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Differences Between the Loading Dose of Prasugrel and Ticagrelor .

NCT02032303

Acute Coronary Syndrome Non ST Elevation Myocardial Infarction ST Elevation Myocardial Infarction +1 more

UNKNOWN PHASE4

NIRS Ticagrelor Evaluation

NCT02282332

Coronary Artery Disease

COMPLETED PHASE4

Prevalence and Characteristics of Transthyretin Amyloidosis in Patients With Left Ventricular Hypertrophy of Unknown Etiology

NCT03842163

Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

COMPLETED

International Takotsubo Registry (InterTAK Registry)

NCT01947621

Takotsubo Cardiomyopathy

UNKNOWN

Comparison Between the New Highly Sensitive Troponin T and the Conventional Troponin T Test in Elderly Patients

NCT01370382

Acute Coronary Syndrome

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is a multi-centre, observational, prospective study to be conducted at 60 hospitals across IndiaThe study will be initiated after obtaining written approval of Independent Ethics Committee (IEC) and written Informed consent of the patient.

Patients who had been hospitalized for ACS and are on ticagrelor on discharge or on Ticagrelor therapy for ≤ 1month will be enrolled in the study and followed up for a period of 12 months. During the follow-up period of up to 12 months (according to the label), assessment visits will follow the routine clinical practice. No visits or measurements will be made mandatory by the protocol

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Coronary Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

one arm

patients on Ticagrelor

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Written informed consent has been provided.
2. Aged 18 years or older.
3. Male/female with ACS on Ticagrelor on discharge or ≤ 1month.
4. Patient underwent PCI, CABG or MM (Medical Management) for ACS.
5. Diagnosis of STEMI, NSTEMI or UA

Exclusion Criteria

1. Patients with medical history of intracranial hemorrhage
2. All those patients who are not fit to receive Ticagrelor as per the latest prescribing information

Eligible Sex

ALL

Accepts Healthy Volunteers

No